Please try another search
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company’s development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Name | Age | Since | Title |
---|---|---|---|
Roger James Pomerantz | 64 | 2020 | Independent Chairman of the Board |
Carl H. June | 68 | 2018 | Member of Scientific Advisory Board |
Lawrence Young | - | 2018 | Member of Scientific Advisory Board |
Charles Cobbs | - | 2018 | Member of Scientific Advisory Board |
Ronald Levy | - | 2018 | Member of Scientific Advisory Board |
Pierluigi Porcu | - | 2018 | Member of Scientific Advisory Board |
Robert Baiocchi | - | 2018 | Member of Scientific Advisory Board |
Corey Casper | - | 2018 | Member of Scientific Advisory Board |
Ivor Royston | 76 | 2007 | Director |
Thomas Eric Darcy | 71 | 2021 | Independent Director |
Stephen Rubino | 64 | 2021 | Independent Director |
Barry J. Simon | 57 | 2021 | Independent Director |
Samuel Lafayette Murphy | 45 | 2019 | Independent Director |
Mark Andrew Rothera | 60 | 2022 | CEO, President & Director |
Jane Chung | 52 | 2022 | Independent Director |
Daniel Douglas Von Hoff | 75 | - | Member of Scientific Advisory Board |
Shannon Kenney | - | - | Member of Scientific Advisory Board |
Jane F. Barlow | 62 | 2021 | Independent Director |
Flavia Borellini | 64 | 2021 | Independent Director |
Gavin Giovannoni | - | 2024 | Member of Scientific Advisory Board |
Douglas V. Faller | - | - | Scientific Founder & Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review